Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | QARS1 | P47897 | 1/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398286 | 0.89 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL27914542 | 0.85 | GRM8 (0.50) | BLMKMT2ANOD1DPP4DPP8 | |
| SCHEMBL2323388 | 0.85 | NOD1 (0.38) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL8009500 | 0.84 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL28364075 | 0.84 | ALOX15 (0.47) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL27956720 | 0.84 | NOD1 (0.49) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL8581073 | 0.84 | NOD1 (0.49) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL8749113 | 0.84 | NOD1 (0.49) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL2732561 | 0.82 | NOD1 (0.54) | ALOX15BLMPMP22KMT2ANOD1 | |
| SCHEMBL6428430 | 0.82 | ALOX15 (0.46) | ALOX15BLMPMP22KMT2ANOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018156514-A1 | PROCESSES FOR MAKING POLYISOBUTYLENE COMPOSITIONS | NTP TEC, LLC (US) | 2018-08-30 | — | — | WO | claimed |
| EP-1578450-A4 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2009-06-17 | — | — | EP | claimed |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. | 2006-06-15 | — | — | US | claimed |
| EP-1578450-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | Access Pharmaceuticals Australia Pty Ltd (AU) | 2005-09-28 | — | — | EP | claimed |
| EP-1206252-A4 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2005-02-16 | — | — | EP | claimed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | claimed |
| EP-0701448-B1 | AMPLIFICATION OF THE VITAMIN B 12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 2002-08-14 | — | — | EP | claimed |
| EP-1206252-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2002-05-22 | — | — | EP | claimed |
| EP-1088020-A1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) | 2001-04-04 | — | — | EP | claimed |
| WO-2000066091-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING POLYMERS | BIOTECH AUSTRALIA PTY LIMITED (AU) | 2000-11-09 | — | — | WO | claimed |
| EP-0700295-A4 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1998-09-30 | — | — | EP | claimed |
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | claimed |
| US-5548064-A | COLONY STIMULATING FACTOR; ORAL ADMINISTERING | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1996-08-20 | — | — | US | claimed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| CN-1126436-A | Vitamin B12 mediated oral delivery systems for GCSF and EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| EP-0700295-A1 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-13 | — | — | EP | claimed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027613-A1 | VITAMIN B12 MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060127310-A1 | Amplification of biotin-mediated targeting | BTD, HLCS, SLC1A5 | ALOX15 3126/4885BLM 4511/4885PMP22 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.